Researchers at the School of Medicine have found that the same mutation that gives tuberculosis bacteria drug resistance also elicits a weaker immune response. The findings are published in Nature Microbiology.
A DNA-based analysis of blood cells soon after a stem cell transplant can predict likelihood of disease recurrence in patients with myelodysplastic syndrome (MDS), a group of cancerous disorders characterized by dysfunctional blood cells, according to new research at the School of Medicine.
The School of Medicine’s Jeffrey I. Gordon, MD, has received a 2018 Luminary Award from the Precision Medicine World Conference. He is being honored for his pioneering work in founding the field of gut microbiome research and for fundamentally altering the understanding of the origins of human health and disease, especially as they relate to nutrition.
A new study from the School of Medicine shows that — in human tumor cells grown in the lab — a natural plant compound shuts down uveal melanoma cell growth.
A new study by the School of Medicine and others identifies mutations associated with relapse in ER positive breast cancer — knowledge that could lead to better therapies.
Hong Chen, assistant professor of biomedical engineering in the School of Engineering & Applied Science and assistant professor of radiation oncology at the School of Medicine, reached across disciplines to work toward a more focused drug delivery system that could target tumors lodged in the brainstem, the body’s most precious system.
An experimental drug reduces brain atrophy in people with progressive multiple sclerosis, raising hopes that it also can reduce disability. The School of Medicine is one of 28 clinical sites participating in the study.
Using technology similar to what is found in many eye doctors’ offices, School of Medicine researchers have detected evidence suggesting Alzheimer’s in older patients who had no symptoms of the disease.
New School of Medicine research, in mice, indicates that a natural sugar called trehalose blocks glucose from the liver and activates a gene that boosts insulin sensitivity, reducing the chance of developing diabetes.
A research team at the School of Medicine has found that laser treatment designed to destroy the deadly brain cancer glioblastoma can add an average of two months to a patient’s life, compared with chemotherapy. The increase is small but meaningful for people who have only months left to live.